dEEGtal develops AI-driven solutions to enhance EEG analysis, starting with a medical device for epilepsy diagnosis. While focused on clinical applications, we are expanding to offer AI models that provide deeper insights into EEG data for neuroscience, pharma, and industry partners.
Products, services, technology
dEEGtal develops AI-powered software to help neurologists diagnose epilepsy with a digital biomarker. We also create scalable AI solutions for industry, reducing EEG model development time and costs. Our model provides quantitative brain metrics, enhancing clinical and research insights.
Cooperation possibilities
dEEGtal seeks collaborations with medtech companies developing AI-powered EEG solutions and pharma partners aiming to better stratify patients or assess CNS drug efficacy. Our adaptive AI model extracts deep insights from EEG data, accelerating innovation in clinical and research applications.
- http://www.deegtal.ai
- +41 79 672 27 68
- Send an email
- Eric Ménétré
Some insights
dEEGtal develops AI-powered software to help neurologists diagnose epilepsy with a digital biomarker. We also create scalable AI solutions for industry, reducing EEG model development time and costs.
We take pride in our dedicated team of senior experts, our deep clinical integration that grants access to valuable data, and our high-performing AI models advancing epilepsy detection. Our work is transforming diagnostics and improving patient care through innovation in neurology.
We admire pioneers like Geoffrey Hinton in deep learning and innovators like Demis Hassabis at DeepMind. Companies such as Insilico Medicine and Tempus inspire us by integrating AI into clinical practice, revolutionizing diagnostics and treatment in healthcare.
Our team excels in neuroscience, AI, and software engineering, driving innovation in EEG analysis. We aim to integrate expertise in regulatory affairs, clinical partnerships, and business development to scale our impact, navigate approvals, and accelerate adoption in healthcare and pharma.
They would say that we teach computers to read brains and help doctors diagnose epilepsy.
The Swiss biotech ecosystem can support us by connecting us with investors, fostering collaborations, and facilitating partnerships with medtech and pharma companies. Access to funding, regulatory guidance, and clinical validation opportunities would accelerate our impact in AI-driven EEG analysis.
We seek connections with investors, medtech companies developing EEG solutions, pharma firms interested in AI-driven patient stratification, regulatory experts for medical device approval, and hospital networks for clinical validation. Strong partnerships will accelerate our impact in healthcare.